Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
HAYWARD, Calif., Jan. 4, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Kurt Graves, Executive Chairman of Intarcia Therapeutics, will present at the 29th Annual JP Morgan Healthcare Conference at 3:30 p.m. PST on Tuesday, January 11, 2011 at the Westin St. Francis Hotel in San Francisco, California.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS® drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity.
About ITCA 650
ITCA 650 is an investigational therapy for the treatment of type 2 diabetes using Intarcia's proprietary drug delivery technology. In 2010, Intarcia completed Phase 2 development of ITCA 650 and is planning to initiate Phase 3 development in 2011. ITCA 650 delivers exenatide therapy from a matchstick-sized, miniature osmotic pump placed subcutaneously. ITCA 650 can deliver up to a full year of therapy from a single administration in a physician's office.
About Type 2 Diabetes
According to the National Institutes of Health (NIH), "Approximately 23.6 million Americans have type 2 diabetes, which represents 7.8 percent of the U.S. population and about 1/4 of them don't even know it. In addition, we now know that at least another 57 million Americans have 'pre-diabetes.'" Diabetes is conservatively estimated to be the seventh leading cause of death in the U.S. Minority populations are disproportionately affected, particularly African Americans and Hispanics. For example, African Americans are 1.8 times more likely to develop type 2 diabetes compared to non-Hispanic whites.
According to the Centers for Disease Control and Prevention (CDC), the rate of new cases of type 2 diabetes has nearly doubled in the U.S. in the last decade with these new cases mirroring an increase in obesity rates - a leading cause of type 2 diabetes.
Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc. DUROS is a registered trademark of ALZA Corporation licensed to Intarcia Therapeutics, Inc. in certain fields.
SOURCE Intarcia Therapeutics, Inc.